Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.810
+0.020 (0.72%)
At close: Sep 17, 2025, 4:00 PM EDT
2.870
+0.060 (2.14%)
After-hours: Sep 17, 2025, 7:52 PM EDT
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
12.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SNGX News
- 13 days ago - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - PRNewsWire
- 15 days ago - Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 4 weeks ago - Why Is Soligenix Stock Soaring On Monday? - Benzinga
- 4 weeks ago - FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - PRNewsWire
- 5 weeks ago - NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewsWire
- 6 weeks ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PRNewsWire
- 2 months ago - Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PRNewsWire